Austrian company Themis is a leader in the development of vaccines against immune diseases and was previously owned by several international investors. Yesterday, MSD announced the acquisition of the company. MSD is combining its vaccine platform with a new COVID-19 vaccine developed by Themis and Institut Pasteur (a European vaccine research institute), a transaction that paves the way for a global fight against coronavirus.
Brandl Talos advised the shareholders of Themis on this landmark deal for the Austrian biotech scene; these include Farallon Capital Management, Global Health Investment Fund, Adjuvent Capital, Wellington Partners Life Sciences, Ventech, Omnes-Fonds, Hadean Ventures and aws Gründerfonds. In addition, Wilson Sonsini Goodrich & Rosati (Robert Ishii & Miranda Biven) advised the shareholders on U.S. law issues.
Themis Bioscience GmbH was represented by McDermott Will & Emery France (Emmanuelle Trombe & David Lipkin) and Herbst Kinsky (Florian Steinhart & Felix Kernbichler).
MSD was represented by Covington & Burling (Catherine J. Dargan & Michael J. Riella) and Wolf Theiss (Hartwig Kienast).
Roman Rericha led the Brandl Talos transaction team, which also included Markus Arzt, Stephan Strass and Matea Plavotic.